Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2026-01-04 Transaction in Own Shar…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the completion of share repurchase cancellation and the resulting changes in shareholding structure. It details the number of shares repurchased and cancelled, the shareholding percentages before and after cancellation, and mentions the filing of related registration changes. The document is short (1124 characters) and focuses on share repurchase and capital changes, not on financial results or reports. Therefore, it fits the category of a company announcement about share repurchase and capital structure changes, which corresponds to the 'Transaction in Own Shares' category (POS).
2026-01-04 Chinese
第七届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the seventh board of directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. It references a related announcement about a project delay but does not contain financial statements or detailed financial data. The content focuses on board meeting decisions and governance matters rather than financial reporting or shareholder voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2025-12-16 Chinese
募投项目延期公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the delay of its fundraising investment projects. It details the amount of funds raised, usage status, reasons for project delays, revised timelines, and the company's measures to ensure project completion. It also includes board and independent director meeting approvals related to the delay. The content focuses on updates about the company's capital raising and the use of those funds, specifically the postponement of investment projects funded by the raised capital. There are no financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory certification or officer attestation, so not RNS. It is not a general regulatory announcement but a specific update on fundraising project progress and delays. Therefore, the document fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including the use and progress of raised funds.
2025-12-16 Chinese
申万宏源证券承销保荐有限责任公司关于北京星昊医药股份有限公司募投项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a securities underwriting and sponsorship company regarding the delay in the use of raised funds by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics about the fundraising, usage, storage, reasons for project delays, revised timelines, and supervisory measures. The content focuses on the status and management of capital raised through a stock issuance and the compliance with regulatory requirements. It is not a full financial report, earnings release, or management discussion, but rather a regulatory compliance and project status update related to capital use. This fits best under Capital/Financing Update (CAP) as it provides an update on fundraising and capital usage progress and delays.
2025-12-16 Chinese
股权激励计划限制性股票解除限售公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the lifting of restrictions on certain restricted stocks under the company's equity incentive plan. It details the number of shares being unlocked, the shareholders involved, their roles, and the reasons for lifting the restrictions. The document includes tables listing shareholders and share quantities, explanations of the reasons for unlocking shares, and statements ensuring no violations or irregularities. There is no financial performance data, no mention of financial results, no regulatory certifications, or legal proceedings. The content focuses on share unlocking and equity incentive plan details, which is related to transactions involving the company's own shares. This fits best under the category of Transaction in Own Shares (POS), which covers share repurchase or issuance activities and related share transactions by the company or insiders. The document is not a report or announcement of a report but a detailed announcement of share unlocking events.
2025-12-02 Chinese
2023年股权激励计划部分股票期权注销完成公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of part of a stock option plan under the company's 2023 equity incentive plan. It details the number of stock options cancelled, the remaining options, and the date of cancellation. It also states that the cancellation will not materially affect the company's financial status or performance. The document references regulatory guidelines related to equity incentive plans and includes a confirmation letter from the securities registration and settlement company. The content is focused on a capital structure change related to stock options, not a full financial report or earnings release. The document length is short (1175 characters) and it is a formal announcement of a stock option cancellation event, which fits the category of Share Issue/Capital Change (SHA).
2025-11-23 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.